Original Research ARTICLE
Acceptance and Commitment Therapy Preceded by Attention Bias Modification on Residual Symptoms in Depression: A 12-month Follow-up.
- 1Hospital of Southern Norway, Norway
- 2Clinical Neuroscience Research Group, Department of Psychology, University of Oslo, Norway
- 3Department of Clinical Neuroscience, Karolinska Institute, Sweden
- 4Department of Psychology, Wichita State University, United States
- 5Psychopharmacology and Emotion Research Laboratory, Department of Psychiatry, University of Oxford, United Kingdom
- 6Department of Psychology, Faculty of Social and Educational Sciences, Norwegian University of Science and Technology, Norway
- 7Division of Psychiatry, Diakonhjemmet Hospital, Norway
Depression is a highly recurrent disorder with limited treatment alternatives for reducing risk of subsequent episodes. This study investigates the effect of group-based acceptance and commitment therapy (ACT) following attention bias modification (ABM) on residual symptoms of depression over a 12-month follow-up. This multisite study consisted of two phases. In phase 1, participants with a history of depression, currently in remission (N = 244), were randomized to either receive 14 days of ABM or a control condition. In phase 2, a quasi- experimental design was adopted, and only participants from the Sørlandet site next received an 8-week group-based ACT intervention. Self-reported and clinician-rated depression symptoms were assessed at baseline, immediately after phase 1 and at 1, 2, 6, and 12 months after the conclusion of phase 1. At 12-month follow-up, participants who received ACT exhibited fewer self-reported and clinician-rated depressive symptoms. There were no significant differences between ACT groups preceded by ABM or a control condition. Group-based ACT successfully decreased residual symptoms in depression over 12 months, suggesting some promise in preventing relapse. ABM did not augment group-based ACT.
Keywords: Acceptance & Commitment Therapy, Attentional Bias Modification (ABM), Depression, residual symptoms., combined treatment
Received: 20 Jun 2019;
Accepted: 14 Aug 2019.
Copyright: © 2019 Østergaard, Lundgren, Rosendahl, Zettle, Jonassen, Harmer, Stiles, Landro and Haaland. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Mr. Tom Østergaard, Hospital of Southern Norway, Arendal, Norway, email@example.com